Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 1.9x - 2.2x | 2.1x |
| Historical Pb Multiple | 1.7x - 2.4x | 2.2x |
| Fair Value | €9.33 - €10.31 | €9.82 |
| Upside | 0.6% - 11.2% | 5.9% |
| Benchmarks | - | Full Ticker |
| Daiichi Sankyo Company, Limited | 456,800.0% | TSE:4568 |
| Takeda Pharmaceutical Company Limited | 450,200.0% | TSE:4502 |
| Kubota Pharmaceutical Holdings Co., Ltd. | 459,600.0% | TSE:4596 |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 176,200.0% | TWSE:1762 |
| Novo Nordisk A/S | - | SET:NOVOB80 |
| Astellas Pharma Inc. | - | DB:YPH |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| 4568 | 4502 | 4596 | 1762 | NOVOB80 | YPH | |||
| TSE:4568 | TSE:4502 | TSE:4596 | TWSE:1762 | SET:NOVOB80 | DB:YPH | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 18.0% | 19.5% | NM- | -14.6% | 21.0% | -23.6% | ||
| 3Y CAGR | 64.1% | -22.3% | NM- | -49.0% | 28.4% | -25.8% | ||
| Latest Twelve Months | 29.1% | -8.7% | 21.2% | -158.3% | 23.5% | 279.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 10.1% | 6.5% | -14513.0% | 17.2% | 33.9% | 6.1% | ||
| Prior Fiscal Year | 12.5% | 3.4% | -3817.9% | 12.7% | 36.0% | 1.1% | ||
| Latest Fiscal Year | 15.7% | 2.4% | -4933.3% | 3.9% | 34.8% | 2.7% | ||
| Latest Twelve Months | 15.4% | 3.1% | -3710.0% | -5.9% | 35.6% | 4.2% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 9.6% | 4.3% | -49.9% | 11.7% | 80.0% | 5.8% | ||
| Prior Fiscal Year | 12.8% | 2.1% | -45.1% | 8.1% | 88.1% | 1.1% | ||
| Latest Twelve Months | 17.9% | 1.9% | -71.4% | -2.1% | 79.2% | 5.2% | ||
| Next Fiscal Year | 21.9% | 1.4% | #NUM! | -2.5% | 65.9% | 2.5% | ||
| Two Fiscal Years Forward | 26.1% | 1.7% | -184.0% | 0.8% | 52.6% | 3.9% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 3.4x | 1.6x | 163.3x | 1.8x | 5.1x | 1.5x | ||
| Price / LTM EPS | 22.0x | 51.5x | -4.4x | -31.0x | 14.3x | 36.4x | ||
| Price / Book | 4.1x | 1.0x | 4.5x | 0.7x | 9.5x | 2.0x | ||
| Price / Fwd Book | 4.1x | 1.1x | 3.5x | 0.7x | 8.6x | 2.0x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.7x | 4.1x | 9.5x | |||||
| Historical P/B Ratio | 1.7x | 2.2x | 2.4x | |||||
| Selected P/B Multiple | 1.9x | 2.1x | 2.2x | |||||
| (x) Book Value | 1,481,792 | 1,481,792 | 1,481,792 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 4568 | 4502 | 4596 | 1762 | NOVOB80 | YPH | |
| Value of Common Equity | 6,511,614 | 7,052,402 | 4,899 | 2,142 | 1,645,217 | 2,867,616 | |
| (/) Shares Outstanding | 1,850.9 | 1,562.0 | 61.2 | 76.9 | 4,468,590.9 | 1,790.3 | |
| Implied Stock Price | 3,518.00 | 4,515.00 | 80.00 | 27.85 | 0.37 | 1,601.74 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 0.20 | 172.83 | |
| Implied Stock Price (Trading Cur) | 3,518.00 | 4,515.00 | 80.00 | 27.85 | 1.86 | 9.27 | |
| Trading Currency | JPY | JPY | JPY | TWD | THB | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 0.20 | 172.83 | |